The general Bev Lkerung and the overall rate of miscarriage is lower than the expected 22% incidence of 14th In addition, there were 53 pregnancies with exposure to naratriptan experienced outcomes.25 Of the 48 exposures in the first quarter there were 42 births, miscarriages, 5 and 1 abortion. It was reported a child living with a birth defect, but the child was also sumatriptan Trichostatin A TSA w Exposed during the first quarter. The other 5 shots w Occurred during the second quarter, and all resulted in live births without M Reported shortcomings. The types of malformations are not reported in the sumatriptan and naratriptan pregnancy registry. Merck and Company unterh One Database similar to rizatriptan, with regular reports lt Ig updates made available on 31 request.
26 July 2006, 74 women were enrolled in the Pregnancy Registry for Maxalt: 67 prospectively and 7 retrospectively. Of the 67 patients included in the fa Interested parties is 11 lost to follow-up and 21 pregnancies were still anh Dependent. Thus, there are data on 35 pregnancies. Among them there were 30 births, fetal death due to an accident in the line sp Th pregnancy, 3 miscarriages and abortions due to chromosomal abnormalities. There are no data in the report made on the timing of drug exposure in these patients. Of the 7 retrospective reported exposures were three babies with birth defects, as shown in Table 5. All were exposed in the first quarter, but not a model with negative consequences of pregnancy was identified because of the small number of reports.
The data collected in the registers of pregnancy for sumatriptan, naratriptan, rizatriptan, and are of greater Ter importance in determining the safety of medicines through a Bev Lkerung which give a high proportion of women Rf Bearing age are used . The gr Te RESTRICTIONS LIMITATION such a registry is that it relies on voluntary reporting from Budding Uncircumcised in the health professions, and often these reports are made retrospectively, after a negative pregnancy test has occurred. Therefore, the information is always incomplete Complete, and m for may have negatively biased. The first clinical study on the use of triptan may need during the pregnancy in 1998 Ver published And included a cohort of women who w While used during pregnancy sumatriptan and contacted voluntarily 1 of 4 participating teratogen information services seeking advice, the potential Teratogenit t of sumatriptan.
27Within first call at 2 years of service were contacted by the patient and asks for plaintiff tion at different pregnancies. A group of diseases, migraine ne and other drug use is not teratogenic and a group that no Migr ne and adjusted h tte, on drugs that has been known to subject without being The results were compared with those of two control groups threat to the F status. A total of 96 women who sumatriptan w Were exposed during pregnancy were followed prospectively, 95 had their first exposure in the first quarter. The authors reported that there were no statistically significant differences between the three groups in the incidence of major congenital malformations, weight gain of pregnant women, live births, spontaneous or therapeutic abortions, S Uglinge premature babies with low birth weight or rates of cesarean sections. As pregnancy registry,